• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Lactones Gamma butyrolactones
• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether

Recent Advances in the Study of (3aS,4R,5S,6aR)-Hexahydro-5-hydroxy-4-(hydroxymethyl)-2H-cyclopentabfuran-2-one (CAS: 76704-05-7)

The compound (3aS,4R,5S,6aR)-Hexahydro-5-hydroxy-4-(hydroxymethyl)-2H-cyclopentabfuran-2-one (CAS: 76704-05-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This bicyclic lactone derivative, characterized by its unique stereochemistry and functional groups, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, biological activity, and potential as a scaffold for drug development.

One of the key advancements in the synthesis of this compound involves the development of more efficient stereoselective routes. A 2023 study published in the Journal of Organic Chemistry demonstrated a novel enzymatic approach to achieve high enantiomeric purity, which is critical for its biological activity. The study highlighted the use of engineered ketoreductases to selectively reduce a precursor ketone, yielding the desired stereoisomer with over 95% enantiomeric excess (ee). This method not only improves yield but also aligns with the growing demand for sustainable and green chemistry practices in pharmaceutical manufacturing.

In terms of biological activity, recent research has explored the compound's interaction with cellular targets. A 2024 paper in ACS Chemical Biology reported that (3aS,4R,5S,6aR)-Hexahydro-5-hydroxy-4-(hydroxymethyl)-2H-cyclopentabfuran-2-one exhibits inhibitory effects on specific enzymes involved in inflammatory pathways. The study utilized X-ray crystallography to elucidate the binding mode of the compound within the active site of the target enzyme, providing insights into its mechanism of action. These findings suggest potential applications in treating inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Another area of interest is the compound's role as a building block for more complex molecules. Researchers have leveraged its rigid bicyclic structure to design analogs with enhanced pharmacokinetic properties. For instance, a 2023 study in Bioorganic & Medicinal Chemistry Letters described the synthesis of a series of derivatives by modifying the hydroxymethyl group. These derivatives were evaluated for their ability to cross the blood-brain barrier, with several candidates showing promise for central nervous system (CNS) drug development. The study underscores the versatility of this scaffold in medicinal chemistry.

Despite these advancements, challenges remain in optimizing the compound's bioavailability and reducing potential off-target effects. A recent review in Drug Discovery Today (2024) emphasized the need for further preclinical studies to assess the long-term safety and efficacy of derivatives based on this scaffold. Additionally, the review called for more collaborative efforts between academic and industrial researchers to accelerate the translation of these findings into clinical applications.

In conclusion, (3aS,4R,5S,6aR)-Hexahydro-5-hydroxy-4-(hydroxymethyl)-2H-cyclopentabfuran-2-one (CAS: 76704-05-7) represents a promising candidate for drug discovery, with recent studies highlighting its synthetic accessibility, biological activity, and potential as a versatile scaffold. Continued research in this area is expected to yield novel therapeutics for a range of diseases, further solidifying its importance in the field of chemical biology and pharmaceutical sciences.

• 62939-82-6(((3aR,4S,5R,6aS)-5-Acetoxy-2-oxohexahydro-2H-cyclopenta[b]furan-4-yl)methyl acetate)
• 57930-46-8([(3ar,4s,5r,6as)-5-hydroxy-2-oxohexahydro-2h-cyclopenta[b]furan-4 -yl]methyl Acetate)
• 84173-27-3(5-hydroxy-hexahydro-cyclopenta[b]furan-2-one)
• 54423-47-1((3Ar,4S,5R,6aS)-5-Hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one)
• 76023-85-3(2H-Cyclopenta[b]furan-2-one,hexahydro-5-hydroxy-, (3aR,5R,6aR)-rel-)
• 118594-34-6(2H-Cyclopenta[b]furan-2-one,hexahydro-5-hydroxy-4-(3-hydroxy-8-methoxyoctyl)-)
• 32233-40-2((-)-Corey Lactone Diol)
• 521323-11-5(5-Hydroxy-4-(hydroxymethyl)hexahydro-2H-cyclopenta[b]furan-2-one)
• 26054-65-9([(3Ar,4S,5R,6aS)-4-(hydroxymethyl)-2-oxo-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-yl] acetate)
• 36269-13-3(Nsc177439)